Pronia Medical Systems

What Pronia Medical Systems does

Pronia Medical Systems, Inc. is a privately held medical device software company founded in 2007 that develops and commercializes GlucoCare, an FDA 510(k)-cleared insulin dosing calculator based on the Yale Protocol. The company is headquartered in Lewisburg, Pennsylvania with an additional office in New York, and operates with 1-10 employees. GlucoCare runs as a web-based application inside a hospital intranet or via HIPAA-compliant cloud deployment, accepting only blood glucose readings as input data and recommending adjustments to continuous insulin infusions, IV glucose supplementation, and timing for subsequent glucose checks. The system differentiates itself by calculating real-time insulin resistance from actual patient response (using four data points: current blood sugar, immediate past blood sugar, time between measurements, and current insulin rate), and offers a novel single-point targeting protocol (GlucoCare-140B) that achieves less than 0.2% hypoglycemia below 70 mg/dl while maintaining mean blood glucose between 140-150 mg/dl. Multiple protocol variants target different glucose ranges (90-120, 100-139, 120-140, 140-160 mg/dl) and a single-point 140 mg/dl target. Deployment options include HIPAA-compliant cloud, VMware virtualized, and traditional on-premise server models. The product also includes EMR integration, customizable reminder alarms, and built-in quality assurance tools with user-level and unit-level performance tracking.

The company's primary customers are hospital intensive care units managing hyperglycemia in critically ill patients, including surgical, medical, transplant, trauma, burn, and oncology critical care settings. Named reference customers include Westchester Medical Center (600 beds), Memorial Sloan-Kettering Cancer Center, Jewish Hospital, Clark Memorial Hospital, and Citrus Valley Health Partners. Revenue is generated through software licensing and subscription contracts (annual or multi-year), with a free cloud-based trial option to lower evaluation friction. Distribution is direct enterprise sales supported by peer testimonials and academic endorsements (notably from Dr. Silvio Inzucchi, the Yale Protocol developer, and Dr. Guillermo Umpierrez at Emory University). The October 2022 partnership with TransformativeMed integrates GlucoCare into a Cerner-based EHR platform, representing the company's most significant channel expansion. Total known external funding is $300,000 raised in 2012, and ownership remains with the original co-founders Michael R. Marvin, MD (CEO/CMO) and Brian J. Besterman, MD (CIO), with no institutional investors or parent company disclosed.

Name

Pronia Medical Systems

Legal name

Pronia Medical Systems, Inc.

Website

https://proniamed.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Short description

Pronia Medical Systems develops GlucoCare, an FDA-cleared insulin dosing calculator based on the Yale Protocol, sold to hospital intensive care units for glycemic management of critically ill patients via cloud, VMware, or on-premise deployment.

Ownership category

akta.pro rank

Headquarters

HQ city

Louisville

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Software License/Subscription: GlucoCare is sold as a software system to hospitals. The company offers multiple installation options including HIPAA-compliant cloud installation, VMware deployment, and standard server model where they provide a pre-loaded server. This suggests a recurring revenue model through software licensing or subscription.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Pronia Medical Systems develops and sells GlucoCare, an FDA 510(k)-cleared clinical decision support software that automates insulin dosing recommendations for hospitalized critically ill patients using the Yale Protocol. The web-based platform runs inside a hospital's intranet or via HIPAA-compliant cloud and integrates with the hospital EMR, offering multiple target protocols (range-based and single-point), IV-to-SQ transition support, customizable alarms, and built-in quality assurance analytics for nursing managers.

Product overview

Pronia Medical Systems offers GlucoCare, a single FDA-cleared insulin dosing calculator platform built on the Yale Protocol. The core GlucoCare IGC System operates as a web-based medical device with multiple protocol variants including GlucoCare-140(B) (targeting 140 mg/dl with intra-protocol boluses), GlucoCare-160 (targeting 160 mg/dl), and traditional range-based protocols (90-120, 100-139, 120-140, 140-160 mg/dl). The platform is delivered through cloud, VMware, or standard server deployment options and includes built-in quality assurance tools. The GlucoCare-140(B) protocol represents the most advanced offering, achieving less than 0.2% hypoglycemia while maintaining mean blood glucose between 140-150 mg/dl.

Differentiator

Problem solved

Functional benefit

Brands

• GlucoCare: FDA-cleared insulin dosing calculator software for managing hyperglycemia in critically ill patients. Based on Yale Protocol. Runs on web browsers within hospital intranet or via cloud. Helps nurses make rapid and safe determinations of insulin dosing recommendations.

Products and services

• GlucoCare IGC System FDA 510(k)-cleared insulin dosing calculator software (classified as a medical device by FDA) that runs on standard web browsers within a hospital intranet or via the cloud. Implements the Yale Protocol to recommend adjustments to continuous insulin infusions, IV glucose or juice, and timing of subsequent glucose checks for critically ill hospitalized patients. Supports multiple protocol variants including range-based targets (90-120, 100-139, 120-140, 140-160 mg/dl) and single-point targets (GlucoCare-140, GlucoCare-160, GlucoCare-140B), records all entries and recommendations, and communicates them to the hospital EMR.
• GlucoCare-140B Protocol Advanced GlucoCare protocol variant targeting a single glucose level of 140 mg/dl (not a range) with intra-protocol insulin boluses designed to reduce overall continuous insulin infusion rates and more rapidly control glucose in the most insulin-resistant critically ill patients. Validated at less than 0.2% hypoglycemia below 70 mg/dl with mean blood glucose between 140-150 mg/dl depending on patient population.

Quantifiable outcome

• <0.2% hypoglycemia < 70 mg/dl
• +3 more outcomes

Named customers7 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

One partnership is on record.

• TransformativeMedcoreTechnology or Integration · 1 October 2022Pronia Medical Systems, Inc and TransformativeMed signed agreement in October 2022 to integrate GlucoCare into TransformativeMed's fully-integrated, Cerner-based platform. This partnership expands GlucoCare's reach by embedding it within a major EHR platform ecosystem.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/proniamed
• LinkedInlinkedin.com/company/pronia-medical-systems

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pronia Medical Systems